Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you were JNJ Novo Nordisk or Celgene and wanted to partner with PharmaCyte and buy into PharmaCyte, or buy out PharmaCyte, wouldn't you want the share count reduced?
Well, if things do get ugly then I would venture to say it will have something to do with those 1 billion shares and no insider buying.
I'm actually not getting impatient. I can continue to wait. However, as I have mentioned before, I remain cautiously optimistic. I'm just concerned about the 1 billion shares and no insider buying. And I'm quite certain that I'm not the only one on this board with these concerns.
Does anyone know the name of Mr. Waggoner's companion/fiancé?
I wonder if she is investing in any biotech companies?
When you consider "the average" research time for biotech companies being 10 to 20 years, I'd say rudygerner' stating "soon" is spot on.
Good morning rudygerner!
Thank you for all your insightful posts.
Don't you mean "legal" situation?
I applaud your optimism. Although, I am one to believe the possibilities of those reported shares simply being shares purchased by private individuals via the institution. This of course is just my own opinion.
I would like to ask of your opinion on the billion shares and no insider buying.
Someone said it disappeared as quick as it appeared ?????
Fantastic!!! Thanks again.
Go Go PharmaCyte!!!
I somewhat agree RC, and I believe you are as cautiously optimistic as I am.
A bit to your point, my concern continues to be the billion shares and no insider buying (Red flags???)
I'm still wishing us all the very best of luck. ;)
Interesting bit on the TD2. Thanks TheBest...
Do you have any more information on that, or any links? tia
Good morning!...
I wouldn't bet on a buyout guys. Won't happen in my opinion.
I mean if you had an acre adjacent to Central Park would you sell it for millions, or build a luxery high-rise and then sell it for billions?. I mean, seriously!.
A buyout won't happen because a partnership is smarter.
Think VALUE in multiples. ;)
Sounds awesome efood! ...and more than likely, doable! :)
Wow! Pour on the speculation :)
Okay, I'll take a stab at it. Maybe those particular two was a suggestion by Jansen, or even something of a requirement/neccessity for further research and trials, during preparation discussions after a tentative partnership agreement was signed. :)
I guess I would think about things like embedded links, or again, information that he for some reason is waiting to make available. jmo
For example..."partner information" that is incorporated into the website. It may be a partnership that for some unknown reason he may not want known yet.
About the new website, I believe that the website cannot be activated because it will disclose new or secret information that John does not yet want known.
Don't forget an added reason to be excited about the upcoming trial.
In the upcoming trial CiaB's parental cell line that produces the enzyme to convert the ifosfamide will undergo further evaluation from the FDA because the CiaB therapy is a biologic, right? So, once the enzyme producing cell line is reevaluated and the therapy is proven....then guess what?
The FDA becomes satisfied with the parental cell line data, and we'll have our "choice" enzyme producing cell line, approved by the FDA, to engineer and convert the cannabidiol/prodrug in the CiaB/cannabinoid therapy.
Go PharmaCyte!
Yeah, I know right?! And North Korea is going to nuke us next week. Soooooo, I was wondering if you would like to sell me your shares at a huge discount? ;)
I am hoping so!!! I'm really really hoping so.
Yeah. I went to PharmaCytes website and didn't see anything.
1 Billion shares:
After studying many different "type shares/shares ownership/warrants/options/share count" articles I've come to my own conclusion that if PMCB "partners" then we shouldn't have to worry about a split because of the company's strong fundamentals. However, if PMCB is bought out, then we should expect a split prior to the buyout. jmo
I encourage anyone curious as I am to do the same.
Maximum return: Prove ...Partner ...Build ...Sell
Hang in there Bayluv, remember the interview with DeMare (w/Facet) back in May...
DeMare explains what few items were left to complete in order for PharmaCyte to file the IND:
Sarah DeMare: “The single most important item PharmaCyte needed to learn from the FDA at the pre-IND meeting was the acceptability of PharmaCyte’s proposed cell line. Without that understanding, PharmaCyte was unable to move forward with the manufacture of its product candidate for the LAPC clinical trial.”
“An IND encompasses many things, dealing with the manufacture and characterization of the product candidate, the clinical study design and nonclinical studies. PharmaCyte’s therapy for pancreas cancer has undergone or been part of several studies, so incorporation of that information into the IND is not ‘rate limiting’ or ‘slowing down the progress towards submitting an IND.’ The clinical study design that PharmaCyte agreed to undertake after meeting with the FDA is currently being drafted. This is also not rate limiting. To conduct the clinical trial, PharmaCyte will need to manufacture, test and release a Master Cell Bank, a Working Cell Bank and the encapsulated live cells. This information is also required to be described and documented in detail in the IND. The manufacture of these items is the rate limiting factor involved in submitting the IND.”
“Before the IND is filed, the following items must be available for inclusion:
(a) Documentation of preclinical work done on the cells.
(b) Toxicology studies.
(c) Documentation of preclinical work done on the capsules themselves.
(d) A wide array of CMC (Chemistry, Manufacturing and Controls) documentation that verifies that the final biologic product (the encapsulated cells) has been produced under current Good Manufacturing Practices (cGMP)-compliant conditions.
(e) Labeling for the final investigational biologic product.
(f) Previous evidence of human experience with the pancreas cancer therapy (low-dose ifosfamide plus Cell-in-a-Box® encapsulated genetically modified human cells).
(h) The Investigator’s Brochure.
(i) The Informed Consent Form
(j) The Case Report Form”
Can you talk about the items on the list in relation to PharmaCyte’s progress and what further rate limiting steps are on the path to filing the IND?
Sarah DeMare: “Documentation of work done on items (a), (b) and (c) and a significant amount of material concerning item (d) have been accumulated to date. As for item (f), publications of Phase 1/2 and Phase 2 trials that were published in scientific journals are “in-house,” as are original clinical reports of those clinical trials. The clinical trial protocol is nearing the “final” stage. Items (h), (i) and (j) will be written by Translational Drug Development (TD2), the Contract Research Organization (CRO) PharmaCyte has retained to conduct the clinical trial in the U.S. and oversee its conduct in Europe by Clinical Network Services (CNS).”
“The rate limiting step to being able to file the IND and, ultimately, begin the clinical trial is the manufacture of the combination drug product. For live cell-based products, a Master Cell Bank or ‘MCB’ first needs to be manufactured, characterized, tested and released. The speed at which the MCB can be produced is dependent on several different things. First, is the availability of starting materials. Some starting materials can have a significant lead-time when ordering, and you cannot begin manufacture until you have all your starting materials. Second, is the growth rate of the live cells. Cells grow at different rates. There isn’t much that can be done to speed up that process. Unfortunately, it is not a 1 to 2-day event. “
I'm guessing KW is using US cell banks because they have the highest in ethical standards....globally.
Now that's theory Jim ;)
...."probably" just a conference room.
Exactly!, as all should well know.
lol MADD are u Canadian?
Yes I've always hated the summer slump
I think that if the US ever legalizes recreational nationwide their supply will exceed megatons.... megatons of high quality supply.... they will have no need for mass volumes of Canadian import .... so, I personally hope the US continues to have problems with legalization for years to come.
I'll agree that using the word close is a bit exaggerating. However, I did mention the "following news" (6 month hard stop) should take us beyond the $1 threshold.
Best, I am in your camp. I would like to think that the PPS will come close to reaching the $1 threshold once the IND is submitted and announced, well within reach of a following spike from more good news. However, you do realize that many reverse splits have been done prior to buyouts don't you?tt
Those who are concerned or in doubt, ask yourself, how much of a struggle would be PMCB have in reducing their share count?
If all options/warrants are exercised then as you well know the shares become fully diluted. Then of coarse following that a reverse split is guaranteed. A reverse split can be a good thing depending on the investors perspective. We can all agree that what's clear and evident is the abnormal share account.
PMCB's awesome fundamentals are definitely trusting. However, I've looked back at a lot of posts illustrating charts, but none that did ever yield a grand surprise.
I can all but guarantee you that it's not published. It starts the 12 month time-clock for tweaking (in necessary). After that it remains pending until approval is granted.
Yes, CEO, employees, all the same. For such a small company it is common to be paid in shares. Shares sold as we all know are filed on the 144. Don't see Ken selling either. ;)